An A-to-Z Regulatory Journey of a Continuous Glucose Monitoring System: Health Canada Class III and FDA Class II Comparative Pathways

This article examines the integration of regulatory classification, clinical evidence, design controls, manufacturing quality, and post-market surveillance for a representative continuous glucose monitoring (CGM) system, a wearable, factory-calibrated, real-time device that measures glucose in interstitial fluid and communicates readings and trends to compatible receiving devices. The article's central lesson is a classification divergence worth examining in detail: a device of this type is generally classified as Class II in the United States under an integrated CGM special-controls framework, while the same underlying device type is classified as Class III in Canada under a different jurisdiction's risk-based rule structure, demonstrating that classification outcomes depend on each jurisdiction's own legal framework and cannot be assumed to transfer directly from one country to another. The article reconstructs the generalized regulatory journey for this device category, addresses a documented warning-letter lifecycle event illustrating the consequences of undocumented device change management, and closes with recommendations for regulatory affairs professionals managing CGM and comparable connected-device programs across multiple jurisdictions.Keywords: continuous glucose monitoring; Class II/III classification divergence; FDA 510(k); Health Canada Class III licence; change control; software lifecycle; regulatory artificial intelligence